Bioventus Inc. (BVS) stock

BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3033% below fair value

$10.86−0.13 (-1.18%)

Close on Nov 12, 2026Market cap $913.24MP/E 13.6Yield –

Bioventus r&d expenses

Research and development expenses are spending on new products and technology.

Bioventus's R&D Expenses for the twelve months ending Sep 26, 2026 was $12.08M, down 2.4% year over year. For fiscal 2025 it was $12.11M, down 13.2% from the year before. The highest annual figure on record is $23.85M in fiscal 2022.

Annual r&d expenses

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$12.11M	-13.2%
FY2024	Dec 31, 2024	$13.95M	+3.8%
FY2023	Dec 31, 2023	$13.45M	-43.6%
FY2022	Dec 31, 2022	$23.85M	+25.3%
FY2021	Dec 31, 2021	$19.04M	+70.0%
FY2020	Dec 31, 2020	$11.20M	+1.3%
FY2019	Dec 31, 2019	$11.06M	–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 26, 2026	$3.44M	+17.5%
Q2 FY2026	Jun 27, 2026	$3.17M	+0.0%
Q1 FY2026	Mar 28, 2026	$2.47M	-18.1%
Q4 FY2025	Dec 31, 2025	$3.01M	-8.1%
Q3 FY2025	Sep 27, 2025	$2.92M	-23.9%
Q2 FY2025	Jun 28, 2025	$3.17M	-24.7%
Q1 FY2025	Mar 29, 2025	$3.01M	+14.6%
Q4 FY2024	Dec 31, 2024	$3.27M	+0.3%
Q3 FY2024	Sep 28, 2024	$3.84M	+27.5%
Q2 FY2024	Jun 29, 2024	$4.21M	+23.9%
Q1 FY2024	Mar 30, 2024	$2.63M	-30.3%
Q4 FY2023	Dec 31, 2023	$3.26M	-45.1%
Q3 FY2023	Sep 30, 2023	$3.02M	-34.7%
Q2 FY2023	Jul 1, 2023	$3.40M	-46.6%
Q1 FY2023	Apr 1, 2023	$3.77M	-45.6%
Q4 FY2022	Dec 31, 2022	$5.95M	-16.3%
Q3 FY2022	Oct 1, 2022	$4.61M	-25.0%
Q2 FY2022	Jul 2, 2022	$6.37M	+31.6%
Q1 FY2022	Apr 2, 2022	$6.93M	+631.6%
Q4 FY2021	Dec 31, 2021	$7.10M	+145.7%
Q3 FY2021	Oct 2, 2021	$6.15M	+72.4%
Q2 FY2021	Jul 3, 2021	$4.84M	+86.3%
Q1 FY2021	Apr 3, 2021	$947.00K	-55.9%
Q4 FY2020	Dec 31, 2020	$2.89M	–
Q3 FY2020	Sep 26, 2020	$3.57M	–
Q2 FY2020	Jun 27, 2020	$2.60M	–
Q1 FY2020	Mar 28, 2020	$2.15M	–